使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good afternoon, ladies and gentlemen, and welcome to the DexCom second quarter earnings release conference call. (Operator Instructions). Please note that this conference is being recorded. I will now turn the call over to Mr. Terry Gregg. Mr. Gregg, you may begin.
各位女士、先生,下午好,歡迎參加 DexCom 第二季財報發布電話會議。(接線員指示)請注意,本次會議將被錄音。現在我將把電話交給 Terry Gregg 先生。Gregg 先生,您可以開始。
- President, CEO
- President, CEO
Thank you, operator. Good afternoon and welcome to DexCom's second quarter 2009 conference call. Joining me on the call today are Steve Pacelli, our Chief Administrative Officer and Jeff Roper, our Chief Financial Officer. I will ask Steve to present our Safe Harbor statement.
謝謝,接線員。各位下午好,歡迎參加 DexCom 2009 年第二季電話會議。今天與我一同參與電話會議的有我們的首席行政官 Steve Pacelli,以及我們的首席財務官 Jeff Roper。我將請 Steve 宣讀我們的「安全港」聲明。
- Chief Administrative Officer
- Chief Administrative Officer
Thanks, Terry. Some of the statements that we will make in today's call may constitute forward-looking statements. These statements reflect management's expectations about future events, operating plans and performance and speak only as of the date hereof. These forward-looking statements involve a number of risks and uncertainties.
謝謝你,Terry。我們在今天電話會議中所做的部分陳述可能構成前瞻性陳述。這些陳述反映管理層對未來事件、營運計畫與績效的預期,且僅以本日為準。這些前瞻性陳述涉及多項風險與不確定性。
A list of the factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is detailed under risk factors and elsewhere in our annual report on Form 10-K, our quarterly reports on Form 10-Q and our other reports as filed with the SEC. We undertake no obligation to update publicly or revise these forward-looking statements for any reason. Terry.
可能導致實際結果與任何此等前瞻性陳述所明示或暗示者存在重大差異之因素清單,已在我們的 Form 10-K 年度報告、Form 10-Q 季度報告以及我們向 SEC 提交的其他報告中的「風險因素」及其他章節詳述。我們不承擔因任何原因公開更新或修訂這些前瞻性陳述之義務。Terry。
- President, CEO
- President, CEO
Thanks, Steve. The agenda today is the establish one. We'll have a financial review by Jess followed by a commercial update of the quarter. We will then discuss our R&D pipeline, update you on our partnerships, and then move to a Q & A session. Jess.
謝謝,Steve。今天的議程與以往相同。我們將先由 Jess 進行財務回顧,接著提供本季的商業進展更新。然後我們會討論研發產品線、更新合作夥伴關係,最後進入問答環節。Jess。
- CFO
- CFO
Thank you, Terry. Following positive momentum from the first quarter, DexCom continued the trend and generated product revenues of $4.1 million during the second quarter of 2009 compared to $1.9 million the same quarter in 2008, an increase of 112%. Sequentially, product revenues for Q2 increased over 54% from the prior quarter. During Q2 we sold 1,925 systems representing an increase of more than 58% from the prior quarter. We also shipped 610 seven plus upgrade kits during the quarter following the launch of our third generation product in March 2009. Sequentially, our revenues were up over 34% from the prior quarter.
謝謝你,Terry。延續第一季的正向動能,DexCom 持續成長,於 2009 年第二季創造產品營收 410 萬美元,相較 2008 年同季的 190 萬美元,成長 112%。以季對季來看,第二季產品營收較上一季增加超過 54%。第二季我們售出 1,925 套系統,較上一季增加超過 58%。此外,在我們於 2009 年 3 月推出第三代產品後,本季亦出貨 610 套 SEVEN PLUS 升級套件。以季對季來看,我們的營收較上一季成長超過 34%。
Total revenue for the second quarter of 2009 was $6.8 million compared to $2 million for the same quarter in 2008 and included $2.6 million in development grant revenue from our development and collaboration agreements. Cost of sales including both product and nonproduct totaled $7.8 million for the quarter. Product costs of sales totaled $4.6 million for Q2 compared to $3.1 million the same quarter in 2008 and our product gross margin loss was $515,000 for Q2 compared to $1.2 million for the same quarter in 2008. We have experienced an improvement in our negative margin primarily due to increased sales volumes in 2009.
2009 年第二季總營收為 680 萬美元,相較 2008 年同季的 200 萬美元;其中包含來自我們開發與合作協議的 260 萬美元開發補助收入。本季銷貨成本(包含產品與非產品)合計 780 萬美元。第二季產品銷貨成本合計 460 萬美元,相較 2008 年同季的 310 萬美元;第二季產品毛利為虧損 51.5 萬美元,相較 2008 年同季毛利虧損 120 萬美元。我們的負毛利率已有所改善,主要係因 2009 年銷售量增加所致。
Development costs of sales totaled $3.2 million for the second quarter of 2009 compared to $249,000 in 2008. The increase in development cost of sales was primarily due to costs related to our development of a hospital based continuous glucose monitoring system pursuant to our agreement with Edwards entered in to during Q4 of 2008. Sequentially, development of cost of sales for the second quarter increased by $1.2 million from Q1 primarily due to additional development efforts for a hospital-based continuous glucose monitoring system.
2009 年第二季開發銷貨成本合計 320 萬美元,相較 2008 年的 24.9 萬美元。開發銷貨成本增加主要係因依據我們於 2008 年第四季與 Edwards 簽訂之協議,開發院內(hospital-based)連續血糖監測系統所產生的成本。以季對季來看,第二季開發銷貨成本較第一季增加 120 萬美元,主要由於院內連續血糖監測系統的額外開發工作。
Research and development expense decreased by approximately $1.3 million totaled $3.5 million in the second quarter of 2008 compared to $4.8 million in 2008. As a reminder R&D costs associated with our development and collaboration agreements with Animas and Edwards are included within development cost of sales.
研發費用約減少 130 萬美元,2009 年第二季為 350 萬美元,相較 2008 年為 480 萬美元。提醒各位,與我們和 Animas 及 Edwards 的開發與合作協議相關的研發成本,已包含在開發銷貨成本之中。
Selling, general and administrative expense totaled $9 million in Q2 of 2009 compared to $7.2 million in 2008. The increase was primarily due to additional marketing, customer service, sales and insurance reimbursement-related costs. Major components of increased SG&A expense included approximately $751,000 higher salaries and payroll-related costs, $411,000 higher commissions and $118,000 in higher temporary employee costs. Sequentially, SG&A expense increased by approximately $1 million from Q1 primarily due to additional customer service, sales commissions and insurance reimbursement-related costs.
2009 年第二季銷售、一般及行政費用(SG&A)合計 900 萬美元,相較 2008 年的 720 萬美元。增加主要係因額外的行銷、客戶服務、銷售以及保險給付(reimbursement)相關成本。SG&A 增加的主要構成包括:薪資及薪資相關成本增加約 75.1 萬美元、佣金增加 41.1 萬美元,以及臨時員工成本增加 11.8 萬美元。以季對季來看,SG&A 較第一季約增加 100 萬美元,主要由於額外的客戶服務、銷售佣金及保險給付相關成本。
As we've discussed during our earnings call held on May 6, 2009, in January of this year we a adopted retrospective accounting guidance that affects how we account for our convertible debt. For Q2 of 2009 and 2008 we recorded $1.2 million and $991,000 respectively of additional non-cash interest expense related to the amortization of the debt discount. We also recorded 713,000 of interest expense relating to the contractual coupon payments for each of the quarters ended in June 2009 and 2008. The impact of adoption of this recent accounting guidance to loss per share was an additional $0.02 and $0.03 per share for the quarters ended June 30, 2009, and 2008 respectively. Going forward we expect to record $1.2 million to $2 million of non-cash interest expense relating to the amortization of the debt discount on a quarterly basis through March of 2012.
如同我們在 2009 年 5 月 6 日的財報電話會議中所討論的,今年 1 月我們採用了一項追溯適用的會計指引,影響我們對可轉換公司債的會計處理。就 2009 年與 2008 年第二季而言,我們分別認列 120 萬美元與 99.1 萬美元的額外非現金利息費用,係與債務折價攤銷相關。我們亦分別就截至 2009 年與 2008 年 6 月止之各季,認列 71.3 萬美元的利息費用,係與合約票息(coupon)支付相關。採用此最新會計指引對每股虧損的影響,分別使截至 2009 年 6 月 30 日與 2008 年 6 月 30 日止之季度每股虧損額外增加 0.02 美元與 0.03 美元。展望未來,我們預期在 2012 年 3 月之前,將按季認列約 120 萬至 200 萬美元的非現金利息費用,係與債務折價攤銷相關。
Our net loss increased to $15.3 million for the second quarter of 2009 compared to $15 million during the same quarter in 2008. Our net loss for Q2 of 2009 included $4.4 million in non-cash expense centered primarily in share-based compensation and expensive or convertible debt discount relating to the adoption as described previously. The loss per share for the quarter was $0.33 based on 45.8 million in weighted average shares outstanding during the quarter. We ended the quarter with $52 million in cash, restricted cash and marketable securities and we had working capital of $37.5 million dollars. I would now like to turn it back to our president and CEO, Terry Gregg.
2009 年第二季淨損增加至 1,530 萬美元,相較 2008 年同季的 1,500 萬美元。2009 年第二季淨損包含 440 萬美元的非現金費用,主要為股份基礎給付(share-based compensation),以及如前所述因採用新會計指引而產生、與可轉換公司債折價相關的費用。該季每股虧損為 0.33 美元,係以該季加權平均流通在外股數 4,580 萬股計算。本季末我們持有現金、受限制現金及有價證券合計 5,200 萬美元,營運資金為 3,750 萬美元。現在我想把電話交回給我們的總裁兼執行長 Terry Gregg。
- President, CEO
- President, CEO
Thanks, Jess. As you might expect, we were extremely pleased with our performance in the second quarter of 2009. Again highlighting some key performance metrics for the second quarter, total product revenue grew approximately 54% sequentially from Q1 2009 to Q2 2009 and was up 112% compared to the second quarter of 2008. We sold 1,925 starter kits for the SEVEN PLUS in the second quarter amounting to a 58% increase in starter kit sales compared to Q1 2009 and up 81% compared to the second quarter of 2008. Finally, we were pleased to see an increase of approximately 34% in sensor revenues quarter to quarter which is, of course, key to our success over the long term. The launch of the SEVEN PLUS has been extremely well received by patients and healthcare providers and we believe CGM is a category that is on the cusp of a major transition and will play an increasingly critical role in diabetes management in coming quarters.
謝謝,Jess。如各位所預期,我們對 2009 年第二季的表現感到非常滿意。再次強調第二季的一些關鍵績效指標:產品總營收自 2009 年第一季到第二季季對季成長約 54%,且較 2008 年第二季成長 112%。我們在第二季售出 1,925 套 SEVEN PLUS 入門套件(starter kits),較 2009 年第一季入門套件銷量增加 58%,且較 2008 年第二季增加 81%。最後,我們也很高興看到感測器營收季對季增加約 34%,這當然是我們長期成功的關鍵。SEVEN PLUS 的上市獲得病患與醫療照護提供者的高度肯定;我們相信 CGM 正處於重大轉變的臨界點,並將在未來幾季於糖尿病管理中扮演愈發關鍵的角色。
At the annual scientific sessions meeting of the American Diabetes Association in June there were over 40 presentations and posters demonstrating the importance of CGM not only in the ambulatory market but in the hospital sector as well. In particular, we were extremely excited by a late breaking poster analyzing data comparing CGM use by MDI patients versus CGM use by pump patients concluding there is no difference in clinical outcome. This something DexCom has been saying for some time. With the newer analog insulins and pens available today, the real key to reducing glycemic variability is utilization of CGM, not the method of insulin administration.
在 6 月美國糖尿病協會(American Diabetes Association)的年度科學會議上,有超過 40 場報告與海報展示 CGM 的重要性,不僅在門診市場,也在醫院領域同樣如此。特別是,我們對一份最新發表的海報感到非常振奮;該海報分析比較 MDI 病患使用 CGM 與幫浦病患使用 CGM 的資料,結論為臨床結果並無差異。這正是 DexCom 一段時間以來一直在強調的觀點。隨著現今較新的類比胰島素與胰島素筆(pen)的普及,降低血糖波動的真正關鍵在於使用 CGM,而非胰島素給藥方式。
We are also pleased to see full year data on the JDRS study on continuous glucose monitoring presented at the ADA. You'll recall that the JDRS CGM trial was the first truly independent study examining the efficacy of CGM in patients with type 1 diabetes over a year-long period. The primary goal was to demonstrate sustained improvement in glycemic control including avoidance of hypoglycemia during a full year of CGM use. Previously published six months results' demonstrated that CGM both improves A1c and reduces incidents of hypoglycemia for patients over 25 years and for all patients who utilize CGM regularly. Results at the one year mark showed that A1c reduction was sustained both in patients who entered the study with an A1c at or above 7% and in those patients who entered the study with an A1c of less than 7%. Perhaps more exciting was the fact that the incidence of hypoglycemia fell significantly in both groups leaving investigators to conclude that patients utilizing CGM frequently are able to significantly reduce episodes of hypoglycemia without an increase in A1c.
我們也很高興看到在 ADA 上發表的 JDRS 連續血糖監測(CGM)研究之全年期數據。各位應該記得,JDRS CGM 試驗是第一項真正獨立的研究,於為期一年的期間內檢視第 1 型糖尿病患者使用 CGM 的療效。其主要目標是證明在全年使用 CGM 的情況下,血糖控制可持續改善,並包含避免低血糖。先前已發表的六個月結果顯示,CGM 不僅可改善 A1c,亦可降低 25 歲以上患者以及所有規律使用 CGM 的患者之低血糖事件發生率。一年期結果顯示,A1c 的降低在兩類患者中皆可維持:入組時 A1c 大於或等於 7% 的患者,以及入組時 A1c 低於 7% 的患者。更令人振奮的是,兩組的低血糖發生率皆顯著下降,使研究人員得出結論:頻繁使用 CGM 的患者能在不提高 A1c 的情況下,顯著減少低血糖發作。
As we look to the balance of 2009, we stress that continued improvement in our back office systems and processing capabilities will be critical to our ability to scale as a top business priority for us. We recognize that the customer's experience is paramount. As evidenced by our performance in the second quarter, we believe we have made tremendous progress in terms of how our back office operates. However, we're still functioning largely on a manual basis and to put it bluntly, we're busting at the seams in our back office. So what have we accomplished during first half of the year and what lies ahead?
展望 2009 年剩餘期間,我們強調,持續改善後台系統與處理能力,將是我們作為首要業務優先事項、實現規模化的關鍵。我們深知客戶體驗至關重要。從我們第二季的表現可見,我們相信在後台運作方式方面已取得巨大進展。然而,我們目前仍主要以人工方式運作;坦白說,我們的後台已接近負荷極限。因此,今年上半年我們完成了哪些工作?接下來又將面臨什麼?
First, we've achieved much better coordination on the front end between our field sales organization and our back office processing group, particularly with respect to the identification, collection and coordination of required patient documentation. Next, we have gained tremendous experience working with our contracted payors and our DME suppliers to streamline the process for submitting and processing of required documentation. That said, we need to continue to push for progress on the reimbursement front, particularly in terms of the adoption of more liberalized coverage policies for CGM which will not only ease the burden on our back office, but will make the technology available to more patients.
首先,我們在前端的現場銷售組織與後台處理團隊之間,已達成更佳的協調,特別是在所需病患文件的辨識、蒐集與協調方面。其次,我們在與簽約付款方以及 DME 供應商合作、以精簡提交與處理所需文件流程方面,累積了大量經驗。即便如此,我們仍需持續推動報銷端的進展,尤其是推動對 CGM 採用更寬鬆的給付/承保政策;這不僅能減輕我們後台的負擔,也能讓更多患者取得這項技術。
We also need to continue to push to add direct reimbursement contracts for DexCom. At this point we feel we have appropriately mapped existing processes and procedures across all customer facing areas including new sales, reorders, benefits investigation and claims processing. We have validated those processes that are working well and have identified and prioritized required changes. Where needed, we expect to implement process change over the coming quarters. We believe we are taking critical steps today to improve the system before we seek to automate it. At the same time we have identified IT needs which will be implemented to support our processes once they have been streamlined likely towards the latter part of this year. We may also explore opportunities to outsource portions of the claims processing, billing and collection functions to the extent economically justified while always retaining our core focus on the customer.
我們也需要持續推動為 DexCom 增加直接報銷合約。目前我們認為,已適當梳理所有面向客戶的領域之既有流程與程序,包括新銷售、再訂購、給付/福利查核以及理賠處理。我們已驗證運作良好的流程,並已辨識、排序所需變更的優先順序。在需要之處,我們預期將於未來幾個季度實施流程變更。我們相信,在尋求自動化之前,先改善系統是我們當下正在採取的關鍵步驟。同時,我們也已辨識 IT 需求;在流程完成精簡後,相關 IT 將於今年稍晚(可能在下半年)導入以支援流程。我們也可能在經濟上合理的前提下,探索將部分理賠處理、帳單與收款職能外包的機會,同時始終保留我們對客戶的核心關注。
In summary, scaling our back office remains one of our key challenges that will take focus and persistence for us to resolve. However, unlike the primary challenge facing our business this time last year, namely reimbursement or lack of there, which was a challenge or lack thereof which was a challenge by action requiring multiple third party players to resolve scaling our back office infrastructure is a challenge that is entirely within our control and, fortunately, I've lived through this type of scaling challenge while at mini med. We will persevere and I believe we will ultimately gain recognition of DexCom as best in class for customer care in diabetes management.
總結而言,後台規模化仍是我們的主要挑戰之一,需要我們專注並持之以恆地加以解決。然而,與去年此時我們業務所面臨的主要挑戰——也就是報銷(或缺乏報銷)——不同;當時的挑戰需要多個第三方參與者採取行動才能解決,而後台基礎設施的規模化則完全在我們可控範圍內。幸運的是,我在 mini med 任職期間曾親身經歷過此類規模化挑戰。我們將堅持不懈,我相信最終 DexCom 將在糖尿病管理的客戶照護方面,獲得同級最佳(best in class)的認可。
Moving to our R&D pipeline. We have long maintained that the continue introduction of Next Generation products with improved performance is key to the long-term success of our business. We are currently in late stage development of our fourth generation short-term sensor and we expect to complete a pivotal trial for this product later this year or early next year and file a PMA supplement with the FDA shortly thereafter. Our goal is to incorporate improvements into this generation sensor to enhance performance and ease of use for our patients. We expect this sentencer will provide our patients with improved [interferent] blocking including an improvement in acetaminophen blocking. We expect the enhanced membrane system will reduce the intermittent interference that patients sometimes experience during the first night of the sensor session and provide the patient a greater accuracy over the full sensor session. We expect this sensor will have a faster warm-up time as compared to the SEVEN PLUS and, finally, we have designed this new sensor to be suited for large volume production which we believe will greatly improve our gross margins as we scale our business.
接著談我們的研發(R&D)產品管線。我們長期以來一直認為,持續推出具更佳效能的下一代產品,是我們業務長期成功的關鍵。我們目前正處於第四代短期感測器的後期開發階段,預期將於今年稍晚或明年初完成該產品的關鍵性試驗(pivotal trial),並在其後不久向 FDA 提交 PMA 補充申請。我們的目標是在此代感測器中納入改良,以提升患者的效能與易用性。我們預期此感測器將為患者提供更佳的[干擾物]阻斷能力,包括提升對乙醯胺酚(acetaminophen)的阻斷效果。我們預期強化的膜系統將降低患者在感測器使用期第一晚有時會遇到的間歇性干擾,並在整個感測器使用期提供更高的準確度。我們預期此感測器相較於 SEVEN PLUS 具有更快的預熱時間;最後,我們將此新感測器設計為適合大批量生產,我們相信這將在業務規模化時大幅改善毛利率。
We are also in the early development stage of a fifth generation short-term sensor. We expect our fifth generation platform to incorporate certain features and attributes currently found in our in-hospital sensor. As a reminder, our in-hospital sensor is being developed in collaboration with Edwards Lifesciences and is a blood dwelling sensor designed specifically for the critical care market. Published data relating to the in-hospital system, although limited, has shown this sensor to be extremely accurate and capable of blocking a wide range of interfering substances. With our fifth generation ambulatory product we expect to translate certain technology from the blood-based hospital sensor in to a subcutaneous sensor. We believe this will create not only the best in place ambulatory glucose sensor, but will also be an ideal candidate for subcutaneous sensing in the hospital outside of the critical care setting.
我們也正處於第五代短期感測器的早期開發階段。我們預期第五代平台將納入目前在我們院內感測器中所具備的某些功能與特性。提醒各位,我們的院內感測器是與 Edwards Lifesciences 合作開發,屬於血液內置(blood dwelling)感測器,專為重症照護市場設計。與院內系統相關的已發表數據雖然有限,但顯示該感測器極為準確,且能阻斷多種干擾物質。對於我們的第五代可攜式(ambulatory)產品,我們預期將把部分源自血液型院內感測器的技術,轉移至皮下感測器。我們相信,這不僅將打造出同級最佳的可攜式血糖感測器,也將成為在非重症照護情境下、於醫院內進行皮下感測的理想候選方案。
Moving on to our partnerships. We continue to make great progress in our collaboration with Edwards Lifesciences relating to the development and commercialization of a hospital-based continuous glucose monitoring system. I mentioned previously the wealth of coverage for CGM at ADA not only for ambulatory use, but for use in the hospital setting as well. In fact, a common theme at the ADA was the belief that the (inaudible) and (inaudible) sugar trials could have both significantly benefited from CGM. Unfortunately, today there is no methodology other than utilizing traditional fingerstick measurements for monitoring glucose levels and controlling hyperglycemia in the hospital.
接著談我們的合作夥伴關係。我們與 Edwards Lifesciences 在開發與商業化院內型連續血糖監測系統方面的合作,持續取得重大進展。我先前提到,在 ADA 上關於 CGM 的報導相當豐富,不僅涵蓋可攜式使用,也涵蓋院內使用。事實上,ADA 上的一個共同主題是:大家相信(聽不清)與(聽不清)血糖試驗若能使用 CGM,可能都會顯著受益。不幸的是,目前在醫院中,除了使用傳統指尖採血(fingerstick)測量之外,並沒有其他方法可用於監測血糖水平並控制高血糖。
We believe we are still on track to complete our development efforts and clinical studies over the next several months to enable us to support Edwards in seeking regulatory approval and launching our first generation product in Europe before year-end. We continue to make steady progress on the development of integrated insulin pumps, CGM systems with our pump partners, Animas Corporation and Insulet Corporation. You'll recall that in January of this year we expanded our relationship with Animas outside the United States. As we work with our team on the development of an OUS product, it became evident that a single global CGM enabled pump offering would best meet the needs of our patients. In order to accomplish this, however, we are required to make certain modifications to our transmitter in order to comply with regulatory requirements outside the US. As a result, we recently amended our agreement with Animas to provide for the development of a modified transmitter to support a global CGM enabled pump launch by Animas in exchange for which Animas has agreed, among other things, to accelerate a portion of the regulatory approval milestone payment upon completion of the modified transmitter. In spite of this change we believe we are on track to complete all development, clinical and regulatory efforts on these joint development projects to enable us to launch first generation products during 2010. However, as you are well aware, the timing of the regulatory process is uncertain.
我們相信,我們仍按計畫在未來數個月內完成開發工作與臨床研究,以便支援 Edwards 申請監管核准,並在年底前於歐洲推出我們的第一代產品。我們也持續與胰島素幫浦合作夥伴 Animas Corporation 與 Insulet Corporation,在整合式胰島素幫浦與 CGM 系統的開發上穩步推進。各位應記得,今年 1 月我們將與 Animas 的合作關係擴展至美國以外地區。當我們與團隊合作開發 OUS 產品時,我們發現提供單一的全球 CGM 幫浦方案最能滿足患者需求。然而,為達成此目標,我們必須對發射器進行若干修改,以符合美國以外地區的監管要求。因此,我們近期修訂了與 Animas 的協議,規劃開發一款經修改的發射器,以支援 Animas 推出全球 CGM 幫浦;作為交換,Animas 同意(除其他事項外)在完成該經修改發射器後,加速支付部分監管核准里程碑款。儘管有此變更,我們仍相信,我們正按計畫完成這些共同開發專案的所有開發、臨床與監管工作,以便在 2010 年推出第一代產品。然而,如各位所熟知,監管流程的時程具有不確定性。
In summary, CGM continues to demonstrate a positive impact on patients' lives not only by keeping patients continuously informed of their glucose trends, but by assisting them in behavior modification that improves their glycemic variability profile. So what does the future hold for DexCom? During the year we've added two true healthcare visionaries to our Board of Directors, Dr. Jonathan Lord and Dr. Eric Topol. We were pleased to learn recently that Dr. Lord and Dr. Topol were both named to Health Spotters Future Health 100 list. This is a list of the 100 most creative and influential innovators working in healthcare today. We believe the vision and leadership these individuals bring to DexCom will help transform our business in the coming years.
總結來說,CGM 持續透過讓患者隨時掌握其葡萄糖趨勢,不僅對患者生活帶來正面影響,並且協助他們進行行為改變,以改善其血糖變異度表現。那麼 DexCom 的未來將會如何?今年我們在董事會新增了兩位真正的醫療保健遠見領袖:Jonathan Lord 醫師與 Eric Topol 醫師。我們很高興最近得知 Lord 醫師與 Topol 醫師雙雙入選 Health Spotters 的 Future Health 100 名單。這份名單列出當今醫療保健領域中最具創意且最具影響力的 100 位創新者。我們相信,這些人士為 DexCom 帶來的願景與領導力,將在未來幾年協助我們轉型並推動業務發展。
As you know, today we are solely focused on the type 1 patient, largely a result of our limited resources. Yet we believe we are just scratching the surface with respect to the addressable market for CGM. For example, at a recent meeting in Colorado presenters identified CGM as a more important tool than SMBG in type 2 patients that are currently on insulin noting that the ability to see trends is much more important in this group than single point measurements. We believe there may be an application for CGM as diagnostic for drug titration in type 2's. We believe CGM may someday supplement, if not entirely replace, A1c as the basis for quantifying successful diabetes management at the quarterly checkup. We believe CGM may someday replace the oral glucose tolerance test for diabetes diagnosis, particularly gestational diabetes. Finally, as we are ultimately a sensor company, we believe that in time we will measure analytes other than glucose using our core sensing technologies. Thank you. We'll now open it up for our Q&A.
如各位所知,目前我們僅專注於第一型糖尿病患者,這在很大程度上是因為我們資源有限。然而,我們相信在 CGM 的可服務市場方面,我們才剛剛觸及表面。舉例來說,在科羅拉多州最近的一場會議上,講者指出,對於目前正在使用胰島素的第二型糖尿病患者而言,CGM 是比 SMBG 更重要的工具,並指出在這一族群中,觀察趨勢的能力遠比單點測量更重要。我們認為 CGM 可能可作為第二型糖尿病用藥劑量調整(titration)的診斷工具。我們相信,未來某一天 CGM 可能會補充,甚至完全取代 A1c,成為每季回診時量化糖尿病管理成效的基礎。我們相信,未來某一天 CGM 可能會取代口服葡萄糖耐受試驗(oral glucose tolerance test)用於糖尿病診斷,特別是妊娠糖尿病。最後,由於我們本質上是一家感測器公司,我們相信隨著時間推進,我們將運用核心感測技術測量除葡萄糖以外的其他分析物(analytes)。謝謝。接下來我們將開放 Q&A。
Operator
Operator
Thank you. (Operator Instructions). Our first question comes from Tom Gunderson from Piper Jaffray. Please go ahead.
謝謝。(接線員指示)。我們的第一個問題來自 Piper Jaffray 的 Tom Gunderson。請開始。
- Analyst
- Analyst
Hi, good afternoon. On the accelerated ramp that you're seeing in sales, you focused a lot on back office and I'm sure as that bottleneck is opening up you're seeing more flow through there, but on the other end on the sales end, Terry, are you at a point where you need to start adding to that sales force or will that stay stable through the end of the year?
嗨,下午好。關於你們看到銷售加速爬升,你們談了很多後台作業,我相信隨著那個瓶頸打開,你們會看到更多量能流過去。但在另一端、也就是銷售端,Terry,你們是否已經到了需要開始擴增銷售團隊的階段,還是到年底都會維持穩定?
- President, CEO
- President, CEO
Tom, the way we look at it right now is we think it's going to stay stable towards the -- till the end of year. We will look at it again as we look at insurance coverage and we certainly, as I've asked the sales force and we've recently hired Rick Doubleday as our VP of Sales and given his 15 years plus experience in the device side of diabetes he's well versed as well, we still have not, in our opinion, penetrated each of the current accounts that we call on to the level that we would want to expand. There's plenty more mining to be done in our existing call points at this point in time. Add to that we still in our -- to be able to leverage the sales force with our partners both Animas and Insulet, we believe that that will provide us with more than enough coverage through the end of the year.
Tom,我們目前的看法是,我們認為到年底之前會維持穩定。我們會在檢視保險給付覆蓋情況時再重新評估;而且我也已要求銷售團隊——我們最近聘請了 Rick Doubleday 擔任銷售副總裁,他在糖尿病醫療器材領域有 15 年以上經驗,也非常熟悉——但我們仍然認為,我們尚未把目前所拜訪的各個既有客戶帳戶滲透到我們希望擴張的程度。就現階段而言,我們在既有拜訪據點仍有很多可以深耕的空間。再加上,我們仍在——為了能與合作夥伴 Animas 與 Insulet 一起槓桿運用銷售團隊,我們相信這將在年底前提供綽綽有餘的覆蓋。
- Analyst
- Analyst
Got it. And then the second question is you've been in various stages of development over the last couple, three years and sales have just started to become a little bit more predictable. Do you have any sense either from your mini med days or from what you're seeing now of any summer seasonality either higher or lower?
了解。第二個問題是,你們在過去兩三年一直處於不同的開發階段,而銷售最近才開始變得比較可預測。你是否能從你在 MiniMed 的經驗,或從你現在看到的情況,判斷夏季是否存在季節性(較高或較低)?
- President, CEO
- President, CEO
Yes. The third quarter is always the challenge. People go on vacation, both patients, educators, physicians. So I always historically and it certainly was the case back in the mini med era where we always kind of held our breath throughout the summer season getting through July and August, particularly if you have -- well, we're not faced with this yet, but particularly if you have an international component. Half of Europe takes off in July, the other half in August. Since we don't have that much revenue yet in that sector, we're not going feel as much, but we're watchful of it. I think on the other side of it you still see the increased demand and every place that we go, every Congress we attend, it's all about CGM and the broader utilization by an increased group of practitioners and patients. So I think they kind of balances out, so I think they kind of balance out.
是的。第三季一向是挑戰。大家去度假,包含患者、衛教師、醫師。所以從歷史上看,我一直——在 MiniMed 時代確實也是如此——我們整個夏季都會有點屏息以待,撐過 7 月與 8 月,尤其是如果你有——我們目前還沒遇到,但尤其是如果你有國際業務成分。歐洲有一半在 7 月休假,另一半在 8 月休假。由於我們在那個區塊的營收目前還不多,所以感受不會那麼強烈,但我們會留意。另一方面,你仍會看到需求增加;而且我們去到的每個地方、參加的每個大會,大家談的都是 CGM,以及更廣泛地被更多臨床人員與患者使用。所以我認為這兩者大致會互相抵銷,所以我認為這兩者大致會互相平衡。
- Analyst
- Analyst
Okay. That's it for me, Terry. Thanks.
好的。我這邊就這些了,Terry。謝謝。
- President, CEO
- President, CEO
All right, Tom.
好的,Tom。
Operator
Operator
Our next question comes from Ben Andrew from William Blair. Please go ahead.
我們的下一個問題來自 William Blair 的 Ben Andrew。請開始。
- Analyst
- Analyst
Good afternoon, guys, just a couple things maybe on the cost of goods side first. You made some progress in the quarter and Jess, you gave some details on. Terry, can you kind of characterize how much further you can go with the current generation product and where you might kind of roll out on gross margin as you get ready for [gen 4] and then what sort of magnitude of a change would you expect with that version?
各位下午好,我有幾點問題,先從銷貨成本(cost of goods)談起。本季你們有一些進展,Jess 也提供了一些細節。Terry,你能否描述一下,以目前這一代產品而言,你們還能再改善多少?以及當你們準備推出 [gen 4] 時,毛利率大概會走到什麼位置?另外,你預期該版本的變化幅度會有多大?
- President, CEO
- President, CEO
I think that's a great question and I'm looking at Steve Pacelli to answer it.
我覺得這是個很好的問題,我想請 Steve Pacelli 來回答。
- Chief Administrative Officer
- Chief Administrative Officer
Yes, Ben. I mean I think what we've spoken to publicly in the past is that kind of under our current sensor configuration we can get to reasonable gross margin, positive gross margin upwards of kind of 60% on the disposable side. To go north of that is where we start looking at needing the gen 4 high volume mass production-type sensor gen 4 and beyond but, yes, I think you'll see in the coming quarters, assuming revenue continues to increase at a decent rate, you'll see us cross over that gross margin threshold and begin to add some contribution from the gross margin side.
是的,Ben。我的意思是,我們過去在公開場合談到的是,在目前的感測器配置下,我們在耗材(disposable)端可以達到合理的毛利率,也就是正毛利率,上看大約 60%。若要再往上,就需要導入第 4 代(gen 4)那種高產量、大量生產型的感測器,也就是 gen 4 以及之後的版本。不過,是的,我認為在接下來幾個季度,假設營收持續以不錯的速度成長,你會看到我們跨過那個毛利率門檻,並開始在毛利端帶來一些貢獻。
- Analyst
- Analyst
Is that something that can happen yet this year?
這件事今年之內就有可能發生嗎?
- Chief Administrative Officer
- Chief Administrative Officer
We believe, so yes.
我們相信可以,是的。
- Analyst
- Analyst
Okay. And as you think about I mean kind of dovetailing with Tom's question, as you think about the sustainable rate, was there something about this quarter that made it an outlier because it was obviously a significant uptick in the 34%. How badly did you strain the back office getting there and if we think about a Q4 rate, could it be materially above this or is it something where Q3 is sort of flattish or down a bit and then Q4 steps up again?
好的。再來,延續 Tom 的問題,當你思考可持續的成長速度時,這一季是否有什麼因素使其成為異常值?因為很明顯成長大幅跳升到 34%。為了達到這個水準,你們後台承受了多大的壓力?如果我們看第四季的速度,是否可能顯著高於本季?還是說第三季大致持平或略降,然後第四季再往上跳一階?
- President, CEO
- President, CEO
Well, we don't give guidance, as you know, on a future basis, but I think my comment that we were busting at the seams is indicative of the challenge of the second quarter. We had no ramp ability, Ben, if you think about it. Back in the old days we had about two to three years to get things kind of organized. This this came upon us very quickly and we continue to struggle. As reimbursement, this being the reimbursement, I think that we can continue to expand from a standpoint but right now the expansion is in more bodies and we'll do that. As Jess mentioned, some of the increase in the SG&A, temporary bodies being hired as well. That's not something that I want to continue to do. I think once we utilize the information technology that is available to us, be sure that we implement it in an appropriate fashion, this thing is much more scalable than what we're experiencing now.
嗯,如你所知,我們不提供未來的指引(guidance),但我提到我們「忙到快爆掉」其實就反映了第二季的挑戰。Ben,如果你想想看,我們沒有任何爬坡(ramp)能力。以前我們大概有兩到三年的時間把事情安排妥當;但這次來得非常快,我們仍在持續掙扎。就給付(reimbursement)而言——這是給付的問題——我認為我們在擴張方面仍能持續推進,但目前的擴張主要是增加人力,我們會這麼做。正如 Jess 提到的,SG&A 增加的一部分也來自於聘用臨時人力。這不是我想要持續做的事。我認為一旦我們善用可用的資訊科技,並確保以適當方式導入,這個業務的可擴展性(scalable)會比我們現在的狀況高得多。
So as we look at Q3 and Q4, Q4 historically in the durable medical equipment business has always been the biggest quarter for a variety of reasons. Meeting their deductible and flex spending plan, so on, so forth. So we'll kind of weather through. Again, I've stated even from last year sequential growth is what the expectation is and without predicting what Q3's going to look like, certainly we are anticipating that we'll continue to see some type of sequential growth. Will it be the delta out -- the same kind of delta we saw Q2 to Q1? It's hard to predict, but overshadowing that is what I call the summer doldrums. So we'll see but, again, I don't want to mislead you or guide you inappropriately.
因此,當我們看第三季與第四季時,在耐用醫療設備(durable medical equipment)產業中,第四季歷來一直是最大的一季,原因有很多,例如達到自付額(deductible)以及彈性支出計畫(flex spending plan)等,諸如此類。所以我們會設法度過。再說一次,我甚至從去年就提過,市場的期待是逐季成長(sequential growth);在不預測第三季會長什麼樣子的前提下,我們確實預期會持續看到某種程度的逐季成長。會不會是像第二季相對第一季那樣的增量(delta)?很難預測,但其上方的主要變數是我所說的夏季低迷期(summer doldrums)。所以我們再看看;不過,再次強調,我不想誤導你或給出不恰當的指引。
- Analyst
- Analyst
No. And just one brief follow-up and I'll jump off, was bottle neck to back office and you've got a big kind of pent up demand from patients that you haven't been able to satisfy or are you sort of regulating that inflow to the system so you're not disappointing patients? Thanks.
不。再簡短追問一下我就不佔線了,是後台作業成為瓶頸,導致病患有一大波你們一直無法滿足的累積需求?還是你們在調控進入系統的流量,以免讓病患失望?謝謝。
- President, CEO
- President, CEO
No. We're regulating the inflow so we're not disappointing patients. I think the challenge is if you look at the wide variety of the payor system where you have some that we can process quite rapidly because they have more liberal coverage, United Healthcare or Aetna as an example have more comprehensive, so we have a better understanding of what the documentation is required, you go to the other end of that paradigm and you get somebody that like the Blue Cross/Blue Shield member network which requires a lot of documentation and so everybody is getting processed in a timely fashion. It's just trying to understand what those requirements are and addressing them in an efficient manner, but we're not putting anybody in a situation where they can't get product.
不。我們是在調控流入量,避免讓病患失望。我認為挑戰在於,如果你看整個保險支付方(payor)體系的多樣性,有些我們可以很快處理,因為他們的給付範圍較寬鬆;例如 United Healthcare 或 Aetna 的保障較全面,所以我們更清楚需要哪些文件。你再看這個光譜的另一端,像 Blue Cross/Blue Shield 的會員網路就需要大量文件,因此大家都能在合理時間內完成處理。重點只是要理解那些要求是什麼,並以有效率的方式去滿足,但我們不會讓任何人陷入拿不到產品的情況。
- Analyst
- Analyst
Great. Thank you, Terry.
很好。謝謝你,Terry。
Operator
Operator
Our next question comes from Bill Plovanic from Canaccord Adams. Please go ahead.
下一個問題來自 Canaccord Adams 的 Bill Plovanic。請開始。
- Analyst
- Analyst
First could you talk about attrition rates? Has there been -- obviously there was an uptick in product revenues but are you seeing any decline in interest rates for existing patients?
首先能否談談流失率(attrition rates)?顯然產品營收有上升,但你們是否看到既有病患的興趣/使用率有任何下降?
- President, CEO
- President, CEO
We've never commented on that to date and it's still always a difficult number, metric for us to get our hands around because there's all different kinds of utilization depending upon the number of boxes of sensors that we send out and right now our focus, to be honest with you, has been on the front end of the process and to do the back end to really begin to analyze that. We have recently hired somebody out of the diabetes industry as a senior person in the CRM portion of our business to begin to do that analysis, but I wouldn't have an answer for you right now.
到目前為止我們從未對外評論過這點,而且這一直是個很難掌握的數字/指標,因為使用情況差異很大,取決於我們寄出多少盒感測器。坦白說,我們目前的重點一直放在流程的前端;至於後端要真正開始做分析,我們正在著手。最近我們從糖尿病產業延攬了一位資深人士,負責我們業務中 CRM 的部分,開始進行那樣的分析,但我現在還無法給你答案。
- Analyst
- Analyst
Okay. Talking about the back office, it sounds like you're going try and start automating as you get the fourth quarter. Is that a fair assumption?
好的。談到後台作業,聽起來你們會在第四季左右開始嘗試自動化。這樣的假設合理嗎?
- President, CEO
- President, CEO
Yes. The latter part of this year, Bill. I think one of the challenges -- I'm sorry. One of the challenges that we go through is looking at what is it that we need to automate? It's quite easy to say we have all of these systems that we acquired when we -- in our ERP system, but we did not and we are in the process of turning them on. We don't want to waste a lot of money and time to automate something that's inefficient. So we're spending a lot of basic almost manufacturing style environment looking at tack times and things, transfer of information, pieces of paper in order to automate it once rather than multiple iterations of that and I think we've got a good idea. Now it's a matter of looking to implement those in a stepwise fashion.
是的,今年下半年,Bill。我認為其中一個挑戰——抱歉——我們面臨的挑戰之一,是要先釐清我們需要自動化的是什麼。很容易說我們在 ERP 系統裡有各種我們在併購時取得的系統,但我們當時並沒有啟用,而現在正在逐步啟用。我們不想浪費大量金錢與時間去自動化一個本來就低效率的流程。所以我們花了很多時間做一些很基礎、幾乎像製造業現場那樣的檢視:看節拍時間(tack times)之類的、資訊轉移、紙本流轉等,目的是把它一次自動化到位,而不是反覆多次迭代。我想我們已經有不錯的方向,接下來就是分階段導入。
- Analyst
- Analyst
Just a few more questions. Going further into the automation, you'd mentioned that you're trying to improve the speed with which you're able to process information with payors. Is there a sense that some payors are going start adopting more liberal policies and what exactly is the conversation? How do you improve that process so that the turn time is sped up going forward?
再問幾個問題。更深入談自動化,你提到你們想提升與支付方處理資訊的速度。是否有跡象顯示某些支付方會開始採用更寬鬆的政策?你們的對話內容具體是什麼?你們要如何改善流程,讓未來的周轉時間(turn time)加快?
- President, CEO
- President, CEO
Yes. I think there's a couple positives. Number one, we mentioned a year along data set from the JDRF trial that identified not only the patients above 7% entering in a reduction, but also those less than 7%. I think as more information becomes available, then that's a prospect randomized independent trial, that's kind of hard to refute at the payor level. We've had some positive tech assessment reviews of this technology as a category and those will ultimately get implemented throughout the system. That just takes time and that's the other factor.
是的。我認為有幾個正面因素。第一,我們提到 JDRF 試驗的一年期資料集,不僅顯示 HbA1c 高於 7% 的病患有改善,也顯示低於 7% 的病患同樣受益。隨著更多資訊出來,那是一項前瞻性、隨機、獨立試驗,在支付方層級其實很難反駁。其次,我們也得到一些對這項技術(作為一個類別)的正面技術評估(tech assessment)審查結果,而這些最終會在整個體系中落地實施;只是需要時間,這是另一個因素。
If we look at these times of devices that have preceded CGM as a category, ultimately people begin to embrace them more aggressively and as a result of that, they begin to diminish their requirements for justification of coverage, and I have to give JDRF a lot of credit in their outreach in that they continue to call on the payor system, as do we, and trying to update them on the value proposition of using CGM and the ultimate goal of reducing healthcare costs, particularly in the US.
如果我們回顧在 CGM 這個類別之前的各類裝置,最終大家會更積極地接受它們;因此,他們也會逐步降低對給付合理性(coverage justification)的要求。我必須高度肯定 JDRF 在對外倡議上的努力,他們持續拜訪支付方體系,我們也一樣,持續向他們更新使用 CGM 的價值主張,以及最終降低醫療成本的目標,特別是在美國。
- Analyst
- Analyst
Okay. And last question, you had spoken briefly about the collaboration with Animas. Is there any update regarding the work you're doing with Insulet?
好的。最後一個問題,你先前簡短提到與 Animas 的合作。那與 Insulet 的合作進展有任何更新嗎?
- President, CEO
- President, CEO
I just would categorize it that both technical teams are racing ahead. The situations are a bit different between the two organizations because the two products are a bit different and so some of the challenges that I mentioned in the terms of the transmitter are not the same type of challenges because the Insulet uses a PDM for programming. So we've got a little bit different situation there. Again, we have an exclusive agreement with Animas OUS and, therefore, we're not bound with Insulet under the same type of criteria. So I would just say that both of them -- we have plenty of bandwidth with both of the organizations and our goal is to launch product on their behalf as soon as possible.
我會把它歸納為:兩邊的技術團隊都在全速推進。兩個組織的情況有些不同,因為兩個產品也有些不同;因此,我先前提到的發射器(transmitter)相關挑戰,在 Insulet 那邊並不是同一類挑戰,因為 Insulet 使用 PDM 來進行程式設定。所以那邊的情況有點不同。再者,我們與 Animas 在美國以外(OUS)有獨家協議,因此我們與 Insulet 並不受同樣條件約束。我只能說,兩邊——我們與兩個組織都有足夠的資源與頻寬,我們的目標是盡快代表他們推出產品。
- Analyst
- Analyst
Okay. Thank you very much for taking the questions.
好的。非常感謝回答問題。
Operator
Operator
(Operator Instructions). Our next question comes from Shawn Fitz from Stephens , Inc. Please go ahead.
(接線員指示)。下一個問題來自 Stephens, Inc. 的 Shawn Fitz。請開始。
- Analyst
- Analyst
Hey, thanks. Terry just a quick commentary on your ADA conference. There's obviously a lot of clinical buzz revolving around CGM. Could you maybe describe to us how the data from the ADA is beginning to change really how the clinical community approach is monitoring and whether or not you're seeing some of that clinical buzz begin to manifest itself on your demand side of the equation?
嗨,謝謝。Terry,想請你快速評論一下你們在 ADA 會議上的情況。顯然臨床界對 CGM 有很多討論熱度。你能否描述一下 ADA 的資料如何開始改變臨床社群對監測方式的做法?以及你是否看到這些臨床熱度開始在需求端反映出來?
- President, CEO
- President, CEO
Yes. Shawn, it's, again, you always come up with such great questions and there's really two factors that we've seen play out here. With all of the press for CGM at ADA I think you're now getting to another level of practitioner where they're beginning -- I don't want to say wake up -- but they're beginning to understand better that this isn't just a product for only those that really aggressively have their patients manage their diabetes. So that's one factor. I think the second factor is the realization that glycemic variability can be controlled regardless of the route of administration of insulin and I think that's probably an even bigger factor that we're seeing out there.
是的。Shawn,你總是提出很好的問題。我們看到的發展大致有兩個因素。第一,隨著 ADA 對 CGM 的大量報導,我認為你現在觸及到另一個層級的臨床工作者,他們開始——我不想說是「醒來」——但他們開始更理解,這不只是給那些非常積極要求病患管理糖尿病的醫師才會用的產品。這是一個因素。第二個因素是大家逐漸意識到:無論胰島素採用何種給藥途徑,血糖變異(glycemic variability)都是可以被控制的。我想這可能是我們在市場上看到更大的因素。
What I've been trying to do is spend a bit more time in the field with our sales force and I will tell you that when you start talking about how patients on MDI can benefit, it is almost an epiphany to some of these physicians who are aggressively managing patients but they tend to, in their term, aggressively manage them with pumps and you start talking about these outcomes and that and it's like you know, I didn't really think about that, but that makes perfectly good sense. So I think we're beginning to see some of that where there may be a lot more patients that are addressable utilizing MDI. I mean they outnumber the pump patients by about 2-1 these days. So I think that's also being embraced. And I think thirdly, and most recently just last month that at this Colorado meeting that I mentioned, during the SMBG session of the meeting it was more about CGM. Now there was a CGM session as well, but one of the key opinion leaders stood up and actually showed a slide and had a person said SMBG and then had a person with a sign on their chest that said the end is near and made the statement that for insulin using type 2 patients CGM should be the standard of care because you're not getting a lot of worthwhile information from single point measurement in the type 2 population.
我一直嘗試花更多時間和我們的銷售團隊一起在第一線。我可以告訴你,當你開始談到使用 MDI 的病患如何受益時,對某些醫師而言幾乎是一種頓悟;這些醫師雖然很積極管理病患,但他們往往——用他們的說法——是用胰島素幫浦來積極管理。當你開始談這些結果與效益時,他們會覺得:你知道,我以前真的沒想到,但這完全說得通。所以我認為我們開始看到這種情況:可透過 MDI 來觸及的病患可能多得多。我的意思是,現在 MDI 病患大約是幫浦病患的 2 倍左右,所以我認為這也正在被接受。第三點,也是最近的情況:就在上個月我提到的科羅拉多會議上,在會議的 SMBG 議程中,討論的更多其實是 CGM。當然也有一個 CGM 議程,但其中一位關鍵意見領袖站起來展示了一張投影片:一個人寫著 SMBG,另一個人胸前掛著牌子寫著「末日將近」,並表示對於使用胰島素的第二型糖尿病病患,CGM 應該成為照護標準(standard of care),因為在第二型族群中,單點測量並不能提供太多有價值的資訊。
So you're beginning to hear more and more of that and that will migrate beyond just the endocrinology level down to the internal medicine who have high insulin practices and treat a fair number of patients afflicted with the disease. So you're just getting that spreading of the word about the utilization of CGM.
所以你開始越來越常聽到這樣的說法,而這股趨勢也會不只停留在內分泌科層級,還會往下延伸到內科醫師——那些有大量胰島素治療業務、並治療相當多受此疾病影響患者的醫師。因此,你會看到關於使用 CGM 的訊息正在擴散。
- Analyst
- Analyst
So, Terry, if we kind of dovetail with that thought process and think a bit over the horizon, can you get where you want to be from a demand standpoint by strictly focusing on the clinical community or is there a patient awareness strategy as we think about this longer term that you all have to attack as well?
那麼,Terry,如果我們順著這個思路往下接著看、並稍微放眼未來,從需求面的角度來看,你們是否能夠僅靠聚焦臨床社群就達到你們想要的位置?或者,從更長期來看,你們也必須同時推動一套病患認知/病患知曉度的策略來攻克這個市場?
- President, CEO
- President, CEO
Well, you always have the patient strategy. I believe the tipping point to CGM will be driven by the patient awareness and the patient demand. Right now we're still at the push portion of it and what I define that as we go call on the clinicians, we call on the educators. They're driving that message to the patients, but the patients are getting much more aware of the technology. There will be a point, and I suspect it's in 2010, that patients will begin to demand the therapy because they are very well educated. They spend a lot of time on the Internet learning what's new in diabetology and what can improve their lot in life and I just think there's a lot of public awareness.
嗯,你永遠都會有病患策略。我相信 CGM 的臨界點將由病患的認知與病患需求所驅動。現在我們仍處於「推動」的階段;我所謂的推動是指:我們去拜訪臨床醫師、拜訪衛教師,他們把這個訊息傳遞給病患,但病患也正變得更了解這項技術。會有一個時間點——我猜是在 2010 年——病患會開始要求這種治療,因為他們受過很好的教育。他們花很多時間在網路上學習糖尿病學有哪些新進展、哪些能改善他們的生活處境;我認為大眾認知正在大幅提升。
I think the other companies in this space are doing a lot in terms of making CGM as a category, making patients more aware of the utility for it in some form or another all the way to artificial pancreas project that everybody's engaged in in this space. So I just think there's a ground swell that is coming, but at a point we've updated our web initiative directly to the patients on several occasions now and will continue to focus that activity. You're not going to see us on television, but there are other DTC programs that I think will be beneficial, primarily focused on media that is directed to patients with diabetes.
我認為這個領域的其他公司也做了很多事情,讓 CGM 作為一個品類被更多人認識,讓病患以某種形式或另一種形式更了解它的效用,甚至一路延伸到大家都在投入的人工胰臟專案。所以我覺得有一股正在形成的浪潮;但在某個時間點,我們也已經多次更新我們直接面向病患的網站倡議,並會持續聚焦這項活動。你不會在電視上看到我們,但我認為還有其他 DTC(直接面向消費者)的方案會有幫助,主要聚焦在面向糖尿病病患的媒體。
- Analyst
- Analyst
Okay, Terry. Thanks. Last question here, in the analyst community we have a tendency to focus on the integrated CGM opportunity maybe to the exclusion of the in-hospital opportunity. With that being said, it seems like Edwards kind of reiterated their time lines recently on their conference call with the intention of having something on the market in Europe by the end of this year. How significant is their go-to market strategy going to be, Terry, do you think with the first generation nonintegrated product? Is this something they aggressively take to market or do they sit back and wait 12 to 18 months until they have an integrated product?
好的,Terry,謝謝。這裡最後一個問題:在分析師社群中,我們往往會把焦點放在整合式 CGM 的機會上,甚至可能因此忽略院內(in-hospital)的機會。話雖如此,Edwards 似乎最近在他們的電話會議上再次重申了時程,打算在今年年底前在歐洲推出上市產品。Terry,你認為他們以第一代非整合式產品的上市策略會有多重要?他們會積極推向市場,還是會先按兵不動、等 12 到 18 個月後有整合式產品再說?
- President, CEO
- President, CEO
Well, no. I think that when you say sit back, I think they want to get this product, this stand alone product, in the hands of the key opinion leaders who will drive awareness. Remember, if you look back over the last 18 to 24 months in this whole debate over the utilization of "intensive glucose management in the ICU" which has really been a misnomer. I mean it hasn't been intense glucose management. It's been intense use of insulin which in many of these [BSNI] sugar or the [bicep] trial caused in the case of the biceps they stopped because of a higher incidents of hypoglycemia. Now they come back and say even if we measured sugar we'd have something to measure hypoglycemia more effectively, probably wouldn't have stopped the trial or the trial outcomes would have been more efficient. I think Edwards wants to take that message into the hospital sector and really get that into the hands of those key opinion leaders so that they can demonstrate. Remember, Shawn, we have not had that clinical ability.
嗯,不會。我想你說的「按兵不動」,他們其實是希望把這個產品——這個獨立式(stand alone)產品——先交到關鍵意見領袖手上,由他們來帶動認知。記得,如果你回顧過去 18 到 24 個月,整個關於「在 ICU 使用『密集血糖管理』」的辯論——其實這個說法一直是個誤稱。我的意思是,那並不是密集血糖管理,而是密集使用胰島素;在許多這些 [BSNI] 的研究或 [bicep] 試驗中,就像 biceps 的案例,他們因為低血糖發生率較高而停止了試驗。現在他們回過頭來說,即便我們有量測血糖,我們也會有更有效的方法去量測低血糖,可能就不會停止試驗,或試驗結果會更有效率。我認為 Edwards 想把這個訊息帶進醫院端,真正把產品交到那些關鍵意見領袖手上,讓他們能夠示範。記得,Shawn,我們一直沒有那樣的臨床能力。
All of our studies have been somewhat limited as we have driven them for product approval purposes. I think you get even a handful of key opinion leaders globally with the product and they're going to have a much different outcome. Obviously the integrated product which is what we call [gen 2] is something that will have the full marketing force of Edwards some time in -- scheduled for some time in 2010 but I think this is important for them to begin to seek those things and I would even throw out kind of the comment there's been this, we'll call it debate, with regards to the types of commercial fingerstick measurement devices in the hospital and their inaccuracy that FDA and ISO have called into question, I mean that just bodes so well for our product with Edwards because we are significantly more accurate than a commercial meter in the hospital sector. So they looked at that as a great selling opportunity as well as begin to drive utilization of CGM in that sector.
我們所有的研究都相對受限,因為我們主要是為了產品核准而推動。我認為只要在全球讓少數幾位關鍵意見領袖拿到產品,結果就會非常不同。當然,整合式產品——也就是我們所稱的 [gen 2]——將在 2010 年某個時間點(預計於 2010 年)由 Edwards 動用完整的行銷力量來推廣;但我認為對他們而言,現在開始去爭取這些事情很重要。我甚至想補充一點:一直以來,大家對於醫院使用的各類商用指尖採血(fingerstick)量測裝置的準確性存在所謂的「辯論」,而 FDA 與 ISO 也對其不準確性提出質疑;這對我們與 Edwards 的產品非常有利,因為在醫院場景中,我們的準確度顯著高於商用血糖機。因此,他們也把這視為一個很好的銷售機會,同時開始推動 CGM 在該領域的使用。
- Analyst
- Analyst
All right, great, Terry. Thanks again for your time and congratulations on the continued progress.
好,Terry,非常好。再次感謝你撥冗,也恭喜你們持續取得進展。
- President, CEO
- President, CEO
Thanks, Shawn.
謝謝,Shawn。
Operator
Operator
We have no further questions at this time. Mr. Gregg, do you have any closing remarks?
目前沒有其他問題。Gregg 先生,您有任何結語要補充嗎?
- President, CEO
- President, CEO
I do. We believe that CGM will continue to become the standard of care for monitoring glucose and in certain situations it will replace fingerstick measurements. These are not just our words. These are the pronouncements of some of the key opinion leaders in the field of diabetes. DexCom is well positioned technologically to lead this transformation. These are very exciting times for DexCom. Thank you.
有的。我們相信 CGM 將持續成為血糖監測的照護標準(standard of care),並在某些情境下取代指尖採血量測。這不只是我們的說法;這也是糖尿病領域一些關鍵意見領袖的公開宣示。DexCom 在技術上具備良好定位,能引領這場轉型。對 DexCom 而言,這是非常令人振奮的時刻。謝謝。
Operator
Operator
Thank you, ladies and gentlemen, this concludes today's conference. Thank you for participating. You may all disconnect.
謝謝各位女士、先生,今天的會議到此結束。感謝各位參與。各位現在可以掛線離開。